Analystreport

ProQR Therapeutics (NASDAQ: PRQR) is now covered by analysts at Raymond James. They set a "strong-buy" rating and a $19.00 price target on the stock.

ProQR Therapeutics N.V. - Ordinary Shares  (PRQR) 
Last proqr therapeutics n.v. - ordinary shares earnings: 2/26 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: proqr.com